Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-30T20:05:31.107Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of Routine Prophylaxis With Vancomycin or Cefazolin for Femoral Neck Fracture Surgery: Microbiological and Clinical Outcomes

Published online by Cambridge University Press:  21 June 2016

Jacques Merrer ,
Laetitia Desbouchages ,
Valérie Serazin ,
Jimmy Razafimamonjy ,
François Pauthier  and
Michel Leneveu
Jacques Merrer*
Affiliation:
Infection Control Unit, Centre Hospitalier de Poissy / St Germain-en-Laye, Poissy, France
Laetitia Desbouchages
Affiliation:
Department of Public Health, the Bacteriology Laboratory, Centre Hospitalier de Poissy / St Germain-en-Laye, Poissy, France
Valérie Serazin
Affiliation:
Molecular Biology Laboratory, Centre Hospitalier de Poissy / St Germain-en-Laye, Poissy, France
Jimmy Razafimamonjy
Affiliation:
Medical Information Unit, Centre Hospitalier de Poissy / St Germain-en-Laye, Poissy, France
François Pauthier
Affiliation:
Department of Orthopedic Surgery, Centre Hospitalier de Poissy / St Germain-en-Laye, Poissy, France
Michel Leneveu
Affiliation:
Department of Public Health, the Bacteriology Laboratory, Centre Hospitalier de Poissy / St Germain-en-Laye, Poissy, France
*
Unité de Lutte Contre les Infections Nosocomiales, Hôpital de Poissy / St Germain-en-Laye, 10 Rue du Champ-Gaillard, 78303 Poissy, France ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To assess the impact of antibiotic prophylaxis on the emergence of vancomycin-resistant strains of Enterococcus faecium, Enterococcus faecalis, and Staphylococcus aureus and the incidence of surgical site infection (SSI) after vancomycin or cefazolin prophylaxis for femoral neck fracture surgery.

Design.

Prospective cohort study.

Setting.

A hospital with a high prevalence of methicillin-resistant S. aureus (MRSA) carriage.

Patients.

All patients admitted with a femoral neck fracture from March 1, 2004 through February 28, 2005 were prospectively identified and screened for MRSA and vancomycin-resistant (VRE) carriage at admission and at day 7. Deep incisional and organ/space SSIs were also recorded.

Results.

Of 263 patients included in the study, 152 (58%) received cefazolin and 106 (40%) received vancomycin. At admission, the prevalence of MRSA carriage was 6.8%; it was 12% among patients with risk factors and 2.2% among patients with no risk factors (P = .002). At day 7 after surgery, there were 6 patients (2%) who had hospital-acquired MRSA, corresponding to 0.7% in the cefazolin group and 5% in the vancomycin group (P = .04); none of the MRSA isolates were resistant to glycopeptides. The rate of VRE carriage at admission was 0.4%. Three patients (1%) had acquired carriage of VRE (1 had E. faecium and 2 had E. faecalis); all 3 were in the cefazolin group (2% of patients) and none in the vancomycin group (P = .27). Eight SSIs (3%) occurred, 4% in the cefazolin group and 2% in the vancomycin group (P = .47).

Conclusions.

This preliminary study demonstrates that cefazolin and vancomycin prophylaxis have similar impacts on the emergence of glycopeptide-resistant pathogens. Neither MRSA infection nor increased rates of SSI with other bacteria were observed in the vancomycin group, suggesting that a larger multicenter study should be initiated.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 27 , Issue 12 , December 2006 , pp. 1366 - 1371
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Mangram, AJ, Horan, TC, Pearson, ML, Silver, LC, Jarvis, WR; Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20:250–278.Google Scholar
2. Bratzler, DW, Houck, PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005; 189:395–404.CrossRefGoogle ScholarPubMed
3. L'Ecuyer, PB, Murphy, D, Little, JR, Fraser, VJ. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis 1996; 22:424–429.Google Scholar
4. Shams, WE, Rapp, RP. Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons. Orthopedics 2004; 27:565–568.Google Scholar
5. Ridgeway, S, Wilson, J, Charlet, A, Kafatos, G, Pearson, A, Coello, R. Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br 2005; 87:844–850.Google Scholar
6. Engemann, JJ, Carmeli, Y, Cosgrove, SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592–598.Google Scholar
7. Huletsky, A, Lebel, P, Picard, FJ, et al. Identification of methicillin-resistant Staphylococcus aureus carriage in less than 1 hour during a hospital surveillance program. Clin Infect Dis 2005; 40:976–981.Google Scholar
8. Merrer, J, Pisica-Donose, G, Leneveu, M, Pauthier, F. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage among patients with femoral neck fractures: implication for antibiotic prophylaxis. Infect Control Hosp Epidemiol 2004; 25:515–517.CrossRefGoogle ScholarPubMed
9. Dodds Ashley, ES, Carroll, DN, Engemann, JJ, et al. Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus . Clin Infect Dis 2004; 38:1555–1560.Google Scholar
10. Lucet, JC, Grenet, K, Armand-Lefevre, L, et al. High prevalence of carriage of methicillin-resistant Staphylococcus aureus at hospital admission in elderly patients: implications for infection control strategies. Infect Control Hosp Epidemiol 2005; 26:121–126.CrossRefGoogle ScholarPubMed
11. Zanetti, G, Goldie, SJ, Platt, R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 2001; 7:820–827.Google Scholar
12. Zanetti, G, Platt, R. Antibiotic prophylaxis for cardiac surgery: does the past predict the future? Clin Infect Dis 2004; 38:1364–1366.Google Scholar
13. Comite de l'Antibiogramme de la Societe Francaise de Microbiologie. Report 2003. Int J Antimicrob Agents 2003; 21:364–391.Google Scholar
14. Tambic, A, Power, EG, Talsania, H, Anthony, RM, French, GL. Analysis of an outbreak of non-phage-typeable methicillin-resistant Staphylococcus aureus by using a randomly amplified polymorphic DNA assay. J Clin Microbiol 1997; 35:3092–3097.Google Scholar
15. Fang, H, Hedin, G. Rapid screening and identification of methicillin-resistant Staphylococcus aureus from clinical samples by selective-broth and real-time PCR assay. J Clin Microbiol 2003; 41:2894–2899.Google Scholar
16. Depardieu, F, Perichon, B, Courvalin, P. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J Clin Microbiol 2004; 42:5857–5860.Google Scholar
17. Hiramatsu, K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998; 104:7S–10S.Google Scholar
18. Smith, TL, Pearson, ML, Wilcox, KR, et al; Glycopeptide-Intermediate Staphylococcus aureus Working Group. Emergence of vancomycin resistance in Staphylococcus aureus . N Engl J Med 1999; 340:493–501.Google Scholar
19. Bratzler, DW, Houck, PM, Richards, C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005; 140:174–182.Google Scholar
20. Cavallo, JD, Hernandez, E, Bouchard, P, Debuysere, H, Buisson, Y. Asymptomatic carriers of vancomycin-resistant enterococci in France: study in an ambulatory population of young subjects. Presse Med 1997; 26:807.Google Scholar
21. Jordens, JZ, Bates, J, Griffiths, DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium . J Antimicrob Chemother 1994; 34:515–528.Google Scholar
22. Endtz, HP, van den Braak, N, van Belkum, A, et al. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. J Clin Microbiol 1997; 35:3026–3031.Google Scholar
23. Guerin, F, Perrier-Gros-Claude, JD, Foissaud, V, Masseron, T, Thierry, J. Vancomycin resistant Enterococcus in France: high prevalence in a young ambulatory care patient population. Presse Med 1998; 27:1427–1429.Google Scholar
24. Klare, I, Heier, H, Claus, H, et al. Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb Drug Resist 1995; 1:265–272.CrossRefGoogle ScholarPubMed
25. Gambarotto, K, Ploy, MC, Turlure, P, et al. Prevalence of vancomycin-resistant enterococci in fecal samples from hospitalized patients and non-hospitalized controls in a cattle-rearing area of France. J Clin Microbiol 2000; 38:620–624.Google Scholar
26. Velasco, D, Perez, S, Pena, F, et al. Lack of correlation between phenotypic techniques and PCR-based genotypic methods for identification of Enterococcus spp. Diagn Microbiol Infect Dis 2004; 49:151–156.Google Scholar
27. Finkelstein, R, Rabino, G, Mashiah, T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002; 123:326–332.Google Scholar
28. Bolon, MK, Morlote, M, Weber, SG, Koplan, B, Carmeli, Y, Wright, SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 2004; 38:1357–1363.CrossRefGoogle ScholarPubMed